The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line everolimus treatment is effective in RCC patients with poor progression-free survival (PFS) in first-line VEGF-targeted therapies.
V. Gruenwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
C. Seidel
No relevant relationships to disclose
J. Busch
No relevant relationships to disclose
M. Fenner
No relevant relationships to disclose
S. Weikert
No relevant relationships to disclose